Patricia Lipinski
Family · Fort Collins, CONPI 1326145491
Payments from drug & device makers
Across 253 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$625
- AbbVie$558
- Astellas Pharma US Inc$247
- Lilly USA, LLC$232
- Pfizer$225
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,43299%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 71 | $1,077 |
| Otsuka America Pharmaceutical, Inc. | 32 | $625 |
| AbbVie | 28 | $558 |
| Astellas Pharma US Inc | 14 | $247 |
| Lilly USA, LLC | 13 | $232 |
| Pfizer | 12 | $225 |
| Boehringer Ingelheim | 13 | $223 |
| GSK | 11 | $216 |
| Amgen | 10 | $201 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $156 |
| Exact Sciences | 7 | $115 |
| Fidia Pharma USA Inc. | 4 | $80 |
| AstraZeneca | 4 | $76 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Biogen | 3 | $70 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Merck | 2 | $30 |
| Alkermes, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Novartis | 1 | $16 |
| Medtronic | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$114
How this compares
$4,487 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 36 | $49,010 |
| OzempicSemaglutide | 21 | $46,185 |
| EliquisApixaban | 19 | $30,229 |
| XareltoRivaroxaban | 17 | $26,140 |
| RexultiBrexpiprazole | 12 | $25,243 |
| TrulicityDulaglutide | 25 | $23,718 |
| Spiriva RespimatTiotropium Bromide | 26 | $17,334 |
| MounjaroTirzepatide | 18 | $17,327 |
| JardianceEmpagliflozin | 11 | $17,217 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,819 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,273 |
| Gabapentin | 158 | $3,452 |
| Levothyroxine Sodium | 423 | $3,374 |
| SynthroidLevothyroxine Sodium | 49 | $3,228 |
| Omeprazole | 208 | $3,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $247 | $49,01036 claims |
| Novo NordiskOzempic | $19 | $46,18521 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $232 | $41,04543 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $223 | $34,55137 claims |
| PfizerEliquis | $225 | $30,22919 claims |
| Johnson & JohnsonXarelto | $17 | $26,14017 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $625 | $25,24312 claims |
| GSKTrelegy Ellipta, Shingrix | $216 | $17,09231 claims |
| AbbVieSynthroid | $558 | $3,22849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Fort Collins
- Courtney WeirFort Collins$30K
- Daphne ProvauFort Collins$22K
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.